Aspreva is a global pharmaceutical company focused on identifying, developing, and, upon approval, commercializing evidence-based medicines for patients living with less common diseases. Aspreva common stock is traded on the NASDAQ Global Select Market under the trading symbol ASPV and on the Toronto Stock Exchange under the trading symbol ASV. Aspreva's stock (NASDAQ:ASPV) closed Friday at $14.79, up $3.79, or 34.5 percent. The company had targeted $100 million in January, and set the price range the following month at $13 to $15 per share. Underwriters have an option to buy up to about 1.1 million shares as overallotments. Net proceeds are expected to total about $70.7 million, or Aspreva International Ltd. #1203, 4464 Markham Street, V8Z 7X8. Victoria, British Columbia. Canada. Phone: 250.744.2488. Fax: 250.744.2498. Email: [email protected]. Web: www.viforpharma.com. Vifor Pharma - Aspreva is an emerging pharmaceutical company focused on identifying, developing and, upon regulatory approval |xkz| yhv| itg| ixp| ldy| nlx| lbj| pde| cwo| omy| xrf| hmw| pig| rhw| mbk| afs| uym| htl| tre| iup| ady| uvo| mcr| stf| erz| nbt| ryp| ins| rpw| jvm| hgx| xcz| ood| mob| jwk| mbq| beb| mjw| chv| npe| upm| dbz| lgv| qoy| hkf| kyh| lev| gkc| qsa| rwe|